Gizmodo reports there's been progress on a male birth-control gel "being developed with the help of several organizations, including the U.S. government's National Institute of Child Health and Human Development, part of the larger NIH." It's now being tested in a larger-scale Phase IIB trial, which involves around 400 couples. [Five milliliters of gel — about a teaspon — is applied to each shoulder blade once a day, reports NBC News.] That trial is still ongoing, but researchers have already begun to pore through some of the available data, which has provided encouraging results. In the summer of 2022, for instance, Diana Blithe, chief of the NICHD's Contraceptive Development Program, reported that the NES/T gel's efficacy rate so far appeared to be on par or even better than contraceptive hormonal options for women...

The findings are still preliminary, and it will take more time for the full Phase II data to be collected and analyzed. But Blithe and her team have been encouraged by everything they've seen to date. In the team's early assessments, the gel appears to be both effective and safe, with minimal side effects for men taking it... Blithe and her colleagues are set to meet with the FDA next year about the steps needed to begin a larger Phase III trial and are still seeking a commercial partner to help bring the NES/T gel to the market.
Initial findings also showed that the contraceptive worked faster than expected, Blithe said, according to NBC News. They add that at least three other companies are also working on male birth control: Also at the Boston conference on Sunday, YourChoice Therapeutics said a very small trial in the U.K. — just 16 men — showed that its nonhormonal pill, YCT-529, was safe and free of side effects. The San Francisco company's nonhormonal pill works by blocking the vitamin A receptor important for male fertility.YourChoice is planning a larger trial, according to CEO Akash Bakshi.

Will appetite-suppressing drugs hurt the sugar industry? Executives from Walmart warned that Ozempic and Zepbound "are impacting food sales," reports Bloomberg, "and multiple analyst surveys have showed that less-hungry customers are spending fewer dollars at grocery stores and restaurants." The drugs, which cut cravings, will result in a decline in calorie consumption in the US of 1.5% to 2.5% by 2035, with a drop of as much as 5% in the consumption of sweets such as baked goods, confectionery and soda, Morgan Stanley analysts including Pamela Kaufman said in a report last month. Morgan Stanley forecast about a 10th of the US population will be on the so-called GLP-1 medications — originally designed to treat diabetes but being used by many as a powerful weight-loss tool — by 2035... Even with tight supplies and sky-high prices limiting uptake of the medications, sales of GLP-1 drugs for both obesity and diabetes already exceeded $19 billion in 2023. The global obesity market alone could top $100 billion by the end of the decade, Goldman Sachs Group Inc. estimates, while Bloomberg Intelligence forecasts $80 billion of sales.

More than 60% of US consumers taking the drugs said they had cut back on sweet treats like candy, ice cream and baked goods, and many said they had either significantly — or entirely — stopped eating those products, according to Morgan Stanley.

"Chinese scientists develop cure for diabetes," reads the headline from the world's second-most widely read English-language newspaper. ("Insulin patient becomes medicine-free in just 3 months.")

The researchers' results were published earlier in May in Cell Discovery, and are now getting some serious scrutiny from the press. The Economic Times cites a University of British Columbia professor's assessment that the study "represents an important advance in the field of cell therapy for diabetes," in an article calling it a "breakthrough" that "marks a significant advancement in cell therapy for diabetes." Chinese scientists have successfully cured a patient's diabetes using a groundbreaking cell therapy... According to a South China Morning Post report, the patient underwent the cell transplant in July 2021. Remarkably, within eleven weeks, he no longer required external insulin. Over the next year, he gradually reduced and ultimately stopped taking oral medication for blood sugar control. "Follow-up examinations showed that the patient's pancreatic islet function was effectively restored," said Yin, one of the lead researchers. The patient has now been insulin-free for 33 months... The new therapy involves programming the patient's peripheral blood mononuclear cells, transforming them into "seed cells" to recreate pancreatic islet tissue in an artificial environment.
Their article calls it "a significant medical milestone" — noting that 140 million people in China have diabetes (according to figures from the International Diabetes Federation).

Thanks to long-time Slashdot reader AmiMoJo for sharing the news.

China's Chang'e-6 probe successfully lands on far side of the moon China's moon probe has "successfully touched down on the far side of the moon," CNN reports, in "a significant step for the ambitious mission that could advance the country's aspirations of putting astronauts on the moon" by 2030.

The mission's ultimate goal is to return to Earth the first samples from the moon's far side, CNN reports. And China's lunar lander "is now expected to use a drill and a mechanical arm to gather up to 2 kilograms of moon dust and rocks from the basin, a crater formed some 4 billion years ago." To complete its mission, the lander will need to robotically stow those samples in an ascent vehicle that made the landing with it. The ascent vehicle will then return to lunar orbit, where it will dock with and transfer the samples to a re-entry capsule, according to mission information provided by the China National Space Administration. The re-entry capsule and orbiter will then travel back to Earth's orbit and separate, allowing the re-entry capsule to make its expected return later this month to the Siziwang Banner Landing Site in China's rural Inner Mongolia region.
The mission began with its launch on May 3 — and is expected to last 53 days. The landing marks the second time a mission has successfully reached the far side of the moon. China first completed that historic feat in 2019 with its Chang'e-4 probe... The technically complex mission is made more challenging due to where it is being conducted. The far side of the moon is out of range of normal communications, which means Chang'e-6 must also rely on a satellite that was launched into lunar orbit in March, the Queqiao-2.

"The seemingly star-cross Boeing Starliner — within minutes of its long-delayed blastoff on the spacecraft's first piloted test flight — was grounded again Saturday," writes CBS News, "when one of three redundant computers managing the countdown from the base of the launch pad ran into a problem, triggering a last-minute scrub."

More details from NPR: With 3:50 left in the countdown, the rocket's computer initiated a hold. The next launch attempt won't happen until at least Wednesday, NASA said.

An issue with one of the three redundant computer systems at the base of the launch pad that are responsible for initiating the launch sequence prompted the automatic halt, said Tory Bruno, the head of United Launch Alliance, the government contractor trying to launch the Starliner. "We do require all three systems to be running — triple redundancy," ULA President and CEO Bruno said at a Saturday afternoon press briefing. "Those three big computers do a health check. ... Two came up normally. The third one came up, but it was slow to come up, and that tripped a red line that created an automatic hold." ULA engineers don't know why the computer halted, and will troubleshoot ground support equipment overnight, NASA said in an update on Saturday evening.

"A Swiss biocomputing startup has launched an online platform that provides remote access to 16 human brain organoids," reports Tom's Hardware: FinalSpark claims its Neuroplatform is the world's first online platform delivering access to biological neurons in vitro. Moreover, bioprocessors like this "consume a million times less power than traditional digital processors," the company says. FinalSpark says its Neuroplatform is capable of learning and processing information, and due to its low power consumption, it could reduce the environmental impacts of computing. In a recent research paper about its developments, FinalSpakr claims that training a single LLM like GPT-3 required approximately 10GWh — about 6,000 times greater energy consumption than the average European citizen uses in a whole year. Such energy expenditure could be massively cut following the successful deployment of bioprocessors.

The operation of the Neuroplatform currently relies on an architecture that can be classified as wetware: the mixing of hardware, software, and biology. The main innovation delivered by the Neuroplatform is through the use of four Multi-Electrode Arrays (MEAs) housing the living tissue — organoids, which are 3D cell masses of brain tissue...interfaced by eight electrodes used for both stimulation and recording... FinalSpark has given access to its remote computing platform to nine institutions to help spur bioprocessing research and development. With such institutions' collaboration, it hopes to create the world's first living processor.
FinalSpark was founded in 2014, according to Wikipedia's page on wetware computing. "While a wetware computer is still largely conceptual, there has been limited success with construction and prototyping, which has acted as a proof of the concept's realistic application to computing in the future."

Thanks to long-time Slashdot reader Artem S. Tashkinov for sharing the article.

On June 3, a "planet parade" of six planets -- Jupiter, Mercury, Uranus, Mars, Neptune and Saturn -- will form a straight line through the pre-dawn sky. Astronomy.com reports: Some 20 minutes before sunrise, all six planets should be visible, though note that Uranus (magnitude 5.9) and Neptune (magnitude 7.8) will be too faint for naked-eye observing and, although they're present in the lineup, will need binoculars or a telescope to spot. But Jupiter (magnitude -2), Mercury (magnitude -1), Mars (magnitude 1), and Saturn (magnitude 1) will all stand out clearly to the naked eye in a line spanning some 73 degrees on the sky.

What's more, a delicate waning crescent Moon is crashing the party as well, standing just to the lower left of Mars. Note, however, that our Moon is not perfectly in line -- that's because Luna's orbit is tilted some 5 degrees with respect to the ecliptic. The next morning, June 4, the crescent Moon does a little better, falling more closely in line a bit farther from Mars. But now Mercury has stepped out of place and stands to Jupiter's lower right (south) as the two planets reach a close conjunction just 7 degrees apart -- not to be missed, especially in binoculars or telescopes!

By June 5, Mercury lies to Jupiter's lower left, replacing the gas giant as the easternmost point in the planetary lineup. And the nearly New Moon (just 2 percent lit) stands above the pair. As June progresses, Mercury quickly ducks out of view, passing close to the Sun before reappearing in the evening sky and leaving us with only five planets in the pre-dawn sky. But those planets continue to form a nice, clean line, stretching nearly 80 degrees from Jupiter to Saturn (with Uranus, Mars, and Neptune in between) by June 30. On this morning, the Moon as rejoined the line, once again a delicate waning crescent about 33 percent lit, hanging perfectly in place to Mars' upper right.

An anonymous reader quotes a report from the New York Times: Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not easy to find on the forest floor. "It doesn't catch the eye," said Dr. Pellicer, who works at the Botanical Institute of Barcelona in Spain. "You would probably step on it and not even realize it." The scientists eventually managed to spot the nondescript fern. When Dr. Pellicer and his colleagues studied it in the lab, they discovered it held an extraordinary secret. Tmesipteris oblanceolata has the largest known genome on Earth. As the researchers described in a study published on Friday, the fern's cells contain more than 50 times as much DNA as ours do. [The analysis revealed the species T. oblanceolata to have a record-breaking genome size of 160.45 Gbp, which is about 7% larger than that of P. japonica (148.89 Gbp). For comparison, the human genome contains about 3.1 Gbp distributed across 23 chromosomes and when stretched out like a ball of yarn, the length of DNA in each cell only measures about 2m.] "Surprisingly, having a larger genome is usually not an advantage," notes Phys.org in a report. "In the case of plants, species possessing large amounts of DNA are restricted to being slow growing perennials, are less efficient at photosynthesis (the process by which plants convert the sun's energy into sugars) and require more nutrients (especially nitrogen and phosphates) to grow and compete successfully with their smaller-genomed neighbors. In turn, such effects may influence the ability of a plant to adapt to climate change and their risk of extinction."

"In animals, some of the largest genomes include the marbled lungfish (Protopterus aethiopicus) at 129.90 Gbp and the Neuse River waterdog (Necturus lewisi) at 117.47 Gbp," reports Phys.org. "In stark contrast, six of the largest-known eukaryotic genomes are held by plants, including the European mistletoe (Viscum album) at 100.84 Gbp."

The retraction rate for European biomedical-science papers increased fourfold between 2000 and 2021, a study of thousands of retractions has found. Nature: Two-thirds of these papers were withdrawn for reasons relating to research misconduct, such as data and image manipulation or authorship fraud. These factors accounted for an increasing proportion of retractions over the roughly 20-year period, the analysis suggests. "Our findings indicate that research misconduct has become more prevalent in Europe over the last two decades," write the authors, led by Alberto RuanoâRavina, a public-health researcher at the University of Santiago de Compostela in Spain.

Other research-integrity specialists point out that retractions could be on the rise because researchers and publishers are getting better at investigating and identifying potential misconduct. There are more people working to spot errors and new digital tools to screen publications for suspicious text or data. Scholarly publishers have faced increased pressure to clear up the literature in recent years as sleuths have exposed cases of research fraud, identified when peer review has been compromised and uncovered the buying and selling of research articles. Last year saw a record 10,000 papers retracted. Although misconduct is a leading cause of retractions, it is not always responsible: some papers are retracted when authors discover honest errors in their work.

The Japanese government is pushing ahead with a plan to make Japan's publicly funded research output free to read. From a report: In June, the science ministry will assign funding to universities to build the infrastructure needed to make research papers free to read on a national scale. The move follows the ministry's announcement in February that researchers who receive government funding will be required to make their papers freely available to read on the institutional repositories from January 2025. The Japanese plan "is expected to enhance the long-term traceability of research information, facilitate secondary research and promote collaboration," says Kazuki Ide, a health-sciences and public-policy scholar at Osaka University in Suita, Japan, who has written about open access in Japan.

The nation is one of the first Asian countries to make notable advances towards making more research open access (OA) and among the first countries in the world to forge a nationwide plan for OA. The plan follows in the footsteps of the influential Plan S, introduced six years ago by a group of research funders in the United States and Europe known as cOAlition S, to accelerate the move to OA publishing. The United States also implemented an OA mandate in 2022 that requires all research funded by US taxpayers to be freely available from 2026. When the Ministry of Education, Culture, Sports, Science and Technology (MEXT) announced Japan's pivot to OA in February, it also said that it would invest around $63 million to standardize institutional repositories -- websites dedicated to hosting scientific papers, their underlying data and other materials -- ensuring that there will be a mechanism for making research in Japan open.

Long before people develop dementia, they often begin falling behind on mortgage payments, credit card bills and other financial obligations, new research shows. The New York Times: A team of economists and medical experts at the Federal Reserve Bank of New York and Georgetown University combined Medicare records with data from Equifax, the credit bureau, to study how people's borrowing behavior changed [PDF] in the years before and after a diagnosis of Alzheimer's or a similar disorder. What they found was striking: Credit scores among people who later develop dementia begin falling sharply long before their disease is formally identified. A year before diagnosis, these people were 17.2 percent more likely to be delinquent on their mortgage payments than before the onset of the disease, and 34.3 percent more likely to be delinquent on their credit card bills. The issues start even earlier: The study finds evidence of people falling behind on their debts five years before diagnosis.

"The results are striking in both their clarity and their consistency," said Carole Roan Gresenz, a Georgetown University economist who was one of the study's authors. Credit scores and delinquencies, she said, "consistently worsen over time as diagnosis approaches, and so it literally mirrors the changes in cognitive decline that we're observing." The research adds to a growing body of work documenting what many Alzheimer's patients and their families already know: Decision-making, including on financial matters, can begin to deteriorate long before a diagnosis is made or even suspected. People who are starting to experience cognitive decline may miss payments, make impulsive purchases or put money into risky investments they would not have considered before the disease.

Private-equity investors have poured billions into healthcare but often game the system, hurting both doctors and patients. From a report: Consolidation is as American as apple pie. When a business gets bigger, it forces mom-and-pop players out of the market, but it can boost profits and bring down costs, too. Think about the pros and cons of Walmart and "Every Day Low Prices." In a complex, multitrillion-dollar system like America's healthcare market, though, that principle has turned into a harmful arms race that has helped drive prices increasingly higher without improving care. Years of dealmaking has led to sprawling hospital systems, vertically integrated health insurance companies, and highly concentrated private equity-owned practices resulting in diminished competition and even the closure of vital health facilities. As this three-part Heard on the Street series will show, the rich rewards and lax oversight ultimately create pain for both patients and the doctors who treat them. Belatedly, state and federal regulators and lawmakers are zeroing in on consolidation, creating uncertainty for the investors who have long profited from the healthcare merger boom.

Consider the impact of massive private-equity investment in medical practices. When a patient with employer-based insurance goes under for surgery, the anesthesiologist's fee is supposed to be determined by market forces. But what happens if one firm quietly buys out several anesthesiologists in the same city and then hikes the price of the procedure? Such a scheme was allegedly implemented by the private-equity firm Welsh, Carson, Anderson & Stowe and the company it created in 2012, U.S. Anesthesia Partners, according to a Federal Trade Commission lawsuit filed last year. It started by buying the largest practice in Houston and then making three further acquisitions, eventually expanding into other cities throughout the state of Texas. In each location, the lawsuit alleges, USAP pursued an aggressive strategy of eliminating competitors by either acquiring them or conspiring with them to weaken competition. As one insurance executive put it in the FTC lawsuit, USAP and Welsh Carson used acquisitions to "take the highest rate of all ... and then peanut butter spread that across the entire state of Texas." In May, U.S. District Judge Kenneth Hoyt dismissed the FTC's unusual step of charging the private-equity investor, Welsh Carson, but allowed the case against USAP to proceed.

With the help of NASA's James Webb Space Telescope (JWST), an international team of astronomers discovered a galaxy at a redshift of 14.32, indicating it existed just 290 million years post-Big Bang. In a NASA release today, Stefano Carniani from Scuola Normale Superiore in Pisa, Italy, and Kevin Hainline from the University of Arizona in Tucson, Arizona, described how this source was found and what its unique properties tell us about galaxy formation: "The instruments on Webb were designed to find and understand the earliest galaxies, and in the first year of observations as part of the JWST Advanced Deep Extragalactic Survey (JADES), we found many hundreds of candidate galaxies from the first 650 million years after the big bang. In early 2023, we discovered a galaxy in our data that had strong evidence of being above a redshift of 14, which was very exciting, but there were some properties of the source that made us wary. The source was surprisingly bright, which we wouldn't expect for such a distant galaxy, and it was very close to another galaxy such that the two appeared to be part of one larger object. When we observed the source again in October 2023 as part of the JADES Origins Field, new imaging data obtained with Webb's narrower NIRCam (Near-Infrared Camera) filters pointed even more toward the high-redshift hypothesis. We knew we needed a spectrum, as whatever we would learn would be of immense scientific importance, either as a new milestone in Webb's investigation of the early universe or as a confounding oddball of a middle-aged galaxy.

In January 2024, NIRSpec observed this galaxy, JADES-GS-z14-0, for almost ten hours, and when the spectrum was first processed, there was unambiguous evidence that the galaxy was indeed at a redshift of 14.32, shattering the previous most-distant galaxy record (z = 13.2 of JADES-GS-z13-0). Seeing this spectrum was incredibly exciting for the whole team, given the mystery surrounding the source. This discovery was not just a new distance record for our team; the most important aspect of JADES-GS-z14-0 was that at this distance, we know that this galaxy must be intrinsically very luminous. From the images, the source is found to be over 1,600-light years across, proving that the light we see is coming mostly from young stars and not from emission near a growing supermassive black hole. This much starlight implies that the galaxy is several hundreds of millions of times the mass of the Sun! This raises the question: How can nature make such a bright, massive, and large galaxy in less than 300 million years?

The data reveal other important aspects of this astonishing galaxy. We see that the color of the galaxy is not as blue as it could be, indicating that some of the light is reddened by dust, even at these very early times. JADES researcher Jake Helton of Steward Observatory and the University of Arizona also identified that JADES-GS-z14-0 was detected at longer wavelengths with Webb's MIRI (Mid-Infrared Instrument), a remarkable achievement considering its distance. The MIRI observation covers wavelengths of light that were emitted in the visible-light range, which are redshifted out of reach for Webb's near-infrared instruments. Jake's analysis indicates that the brightness of the source implied by the MIRI observation is above what would be extrapolated from the measurements by the other Webb instruments, indicating the presence of strong ionized gas emission in the galaxy in the form of bright emission lines from hydrogen and oxygen. The presence of oxygen so early in the life of this galaxy is a surprise and suggests that multiple generations of very massive stars had already lived their lives before we observed the galaxy.

All of these observations, together, tell us that JADES-GS-z14-0 is not like the types of galaxies that have been predicted by theoretical models and computer simulations to exist in the very early universe. Given the observed brightness of the source, we can forecast how it might grow over cosmic time, and so far we have not found any suitable analogs from the hundreds of other galaxies we've observed at high redshift in our survey. Given the relatively small region of the sky that we searched to find JADES-GS-z14-0, its discovery has profound implications for the predicted number of bright galaxies we see in the early universe, as discussed in another concurrent JADES study (Robertson et al., recently accepted). It is likely that astronomers will find many such luminous galaxies, possibly at even earlier times, over the next decade with Webb. We're thrilled to see the extraordinary diversity of galaxies that existed at Cosmic Dawn!

Satellite-to-phones service provider AST SpaceMobile announced a deal with Verizon to provide remote coverage across the United States. "Verizon's deal effectively includes a $100 million raise for AST, as well, in the form of $65 million in commercial service prepayments and $35 million in debt via convertible notes," reports CNBC. "The companies said that $45 million of the prepayments 'are subject to certain conditions' such as needed regulatory approvals and signing of a definitive commercial agreement." Shares of AST jumped 69% in trading to close at $9.02 a share -- the largest single day rise for the company's stock since it went public in 2021. From the report: AST SpaceMobile is building satellites to provide broadband service to unmodified smartphones, in the nascent "direct-to-device" communications market. [...] The Verizon partnership follows a similar pattern to AT&T's work with AST. Back in January, AT&T was a co-debt investor in the company alongside Google and Vodafone. The companies then established the commercial agreement earlier this month, which "lays out in much more detail how we will ultimately offer service together," AST's Chief Strategy Officer Scott Wisniewski said in a statement to CNBC. [...] AST expects to launch its first five commercial satellites later this year.

An anonymous reader quotes a report from the BBC: A sophisticated joint European-Japanese satellite has launched to measure how clouds influence the climate. Some low-level clouds are known to cool the planet, others at high altitude will act as a blanket. The Earthcare mission will use a laser and a radar to probe the atmosphere to see precisely where the balance lies. It's one of the great uncertainties in the computer models used to forecast how the climate will respond to increasing levels of greenhouse gases. "Many of our models suggest cloud cover will go down in the future and that means that clouds will reflect less sunlight back to space, more will be absorbed at the surface and that will act as an amplifier to the warming we would get from carbon dioxide," Dr Robin Hogan, from the European Centre for Medium-Range Weather Forecasts, told BBC News.

The 2.3-tonne satellite was sent up from California on a SpaceX rocket. The project is led by the European Space Agency (ESA), which has described it as the organization's most complex Earth observation venture to date. Certainly, the technical challenge in getting the instruments to work as intended has been immense. It's taken fully 20 years to go from mission approval to launch. Earthcare will circle the Earth at a height of about 400km (250 miles). It's actually got four instruments in total that will work in unison to get at the information sought by climate scientists.

The simplest is an imager -- a camera that will take pictures of the scene passing below the spacecraft to give context to the measurements made by the other three instruments. Earthcare's European ultraviolet laser will see the thin, high clouds and the tops of clouds lower down. It will also detect the small particles and droplets (aerosols) in the atmosphere that influence the formation and behavior of clouds. The Japanese radar will look into the clouds, to determine how much water they are carrying and how that's precipitating as rain, hail and snow. And a radiometer will sense how much of the energy falling on to Earth from the Sun is being reflected or radiated back into space.